Amphotericin B in liposomes: A novel therapy for histoplasmosis

R. L. Taylor, D. M. Williams, P. C. Craven, J. R. Graybill, D. J. Drutz, W. E. Magee

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


Incorporation of amphotericin B into liposomes significantly altered its toxicity, tissue distribution, and efficacy. Compared with intravenously administered amphotericin B-desoxycholate, liposome-amphotericin B showed a reduced acute toxicity and a maximal tolerable dose 9 times greater than amphotericin B-desoxycholate. Liposome-amphotericin B also produced higher tissue and lower serum concentrations than amphotericin B-desoxycholate, and was significantly more effective in prolonging survival of mice infected with Histoplasma casulatum.

Original languageEnglish (US)
Pages (from-to)610-611
Number of pages2
JournalUnknown Journal
Issue number5
StatePublished - 1982
Externally publishedYes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Amphotericin B in liposomes: A novel therapy for histoplasmosis'. Together they form a unique fingerprint.

Cite this